Chemistry:Depatuxizumab mafodotin

From HandWiki
Short description: Monoclonal antibody
Depatuxizumab mafodotin
Mafodotin ADCs.svg
Monoclonal antibody
TypeWhole antibody
SourceChimeric/Humanized hybrid (mouse/human)
TargetEGFR
Clinical data
Other namesABT-414
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6624H10228N1728O2052S42
Molar mass148251.25 g·mol−1

Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3][4]

This drug was developed by AbbVie. In May 2019 AbbVie stopped enrolment in all studies of Depatux-M after late-stage failure in newly diagnosed glioblastoma.[5]

In 2014, Orphan Drug Status was granted by the FDA for glioblastoma multiforme.[6] It is in phase II/III clinical trials for glioblastoma, in phase II clinical trials for non-small cell lung cancer, and in phase I clinical trials for the treatment of other solid tumors.[7] Phase I results were presented at ASCO in 2016.[7]

References